Safe Accelerated Venetoclax Escalation: a phase 1b study of obinutuzumab plus venetoclax with daily ramp-up in CLL
Jennifer L. Crombie, Inhye E. Ahn, Yue Ren, Svitlana Tyekucheva et autres
0 citationsBlood Advances
Inhye E. Ahn
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
335Publications signalées
3072Citations signalées
1Affiliations récentes
Institutions déclarées
Domaines associés
Chronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and TreatmentGalectins and Cancer BiologyImmunodeficiency and Autoimmune DisordersChronic Myeloid Leukemia Treatments
Publications récentes
A decade of ibrutinib for CLL with and without TP53 aberration: final report on an investigator-sponsored phase 2 study
Andy Itsara, Victoria Rogness, Laura Samples, Constance M. Yuan et autres
3 citationsBlood
Supplementary Table S9 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy
Anfal Alsadhan, Jonathan Chen, Erika M. Gaglione, Chingiz Underbayev et autres
0 citations
Supplementary Table S1 from B-cell Receptor Pathway Mutations Are Infrequent in Patients with Chronic Lymphocytic Leukemia on Continuous Ibrutinib Therapy
Jennifer A. Woyach, Paolo Ghia, John C. Byrd, Inhye E. Ahn et autres
0 citations
Supplementary Table S10 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy
Anfal Alsadhan, Jonathan Chen, Erika M. Gaglione, Chingiz Underbayev et autres
0 citations
Supplementary Figure S1 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy
Anfal Alsadhan, Jonathan Chen, Erika M. Gaglione, Chingiz Underbayev et autres
0 citations
Supplementary table S2 from B-cell Receptor Pathway Mutations Are Infrequent in Patients with Chronic Lymphocytic Leukemia on Continuous Ibrutinib Therapy
Jennifer A. Woyach, Paolo Ghia, John C. Byrd, Inhye E. Ahn et autres
0 citations
Supplementary Figure S5 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy
Anfal Alsadhan, Jonathan Chen, Erika M. Gaglione, Chingiz Underbayev et autres
0 citations
Supplementary Figure S4 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy
Anfal Alsadhan, Jonathan Chen, Erika M. Gaglione, Chingiz Underbayev et autres
0 citations
Supplementary Table S6 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy
Anfal Alsadhan, Jonathan Chen, Erika M. Gaglione, Chingiz Underbayev et autres
0 citations
Supplementary Table S3 from B-cell Receptor Pathway Mutations Are Infrequent in Patients with Chronic Lymphocytic Leukemia on Continuous Ibrutinib Therapy
Jennifer A. Woyach, Paolo Ghia, John C. Byrd, Inhye E. Ahn et autres
0 citations
Supplementary Table S3 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy
Anfal Alsadhan, Jonathan Chen, Erika M. Gaglione, Chingiz Underbayev et autres
0 citations
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.